Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats

Journal of Physiology and Pharmacology

Volumn 61, Issue 3, 2010, Pages 317-324

  Kramkowski, K ^a   Mogielnicki, A ^a   Leszczynska, A ^a   Buczko, W ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Angiotensin 1 9; Angiotensinconverting enzyme inhibitors; Arterial thrombosis; Fibrin; Fibrinogen; Platelets; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-9]; FIBRINOGEN; LOSARTAN; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I (1-9); PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CAROTID ARTERY; CELL FREE SYSTEM; CONTROLLED STUDY; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTEIN FUNCTION; PROTHROMBIN TIME; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE AGGREGATION; THROMBOGENESIS; WISTAR RAT; ANIMAL; ARTERY; BLOOD; DRUG EFFECTS; HUMAN; METABOLISM; THROMBOCYTE; THROMBOSIS;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ARTERIES; BLOOD PLATELETS; HUMANS; LOSARTAN; MALE; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PROTHROMBIN TIME; RATS; RATS, WISTAR; THROMBOSIS;

EID: 77957074578     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002; 40: 774-779.
2. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W. Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 2005; 93: 1069-1076.
3. Kaminska M, Mogielnicki A, Stankiewicz A, et al. Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. J Physiol Pharmacol 2005; 56: 571-585.
4. Nishimura H, Tsuji H, Masuda H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1189-1195.
5. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 2000; 11: 61-69.
6. Larsson PT, Schwieler JH, Wallen NH, Hjemdahl P. Acute effects of angiotensin II on fibrinolysis in healthy volunteers. Blood Coagul Fibrinolysis 1999; 10: 19-24.
7. Ding YA, MacIntyre DE, Kenyon CJ, Semple PF. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost 1985; 54: 717-720.
8. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-1435.
9. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-677.
10. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-1178.
11. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
12. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
13. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
14. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
15. Chabielska E, Pawlak R, Golatowski J, Buczko W. The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats. J Physiol Pharmacol 1998; 49: 251-260.
16. Bavry AA, Li D, Zander DS, Phillips MI, Mehta JL. Inhibition of arterial thrombogenesis by quinapril but not losartan. J Cardiovasc Pharmacol Ther 2000; 5: 121-127.
17. Wojewodzka-Zelezniakowicz M, Chabielska E, Mogielnicki A, et al. Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats. J Physiol Pharmacol 2006; 57: 231-245.
18. Johnson H, Kourtis S, Waters J, Drummer OH. Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin. Peptides 1989; 10: 489-492.
19. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infracted rat. Hypertension 2006; 48: 572-578.
20. Kikuchi M, Fukuyama K, Hirayama K, Epstein WL. Purification and characterization of carboxypeptidase from terminally differentiated rat epidermal cells. Biochim Biophys Acta 1989; 991: 19-24.
21. Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase Alike activity. Circulation 1997; 95: 1455-1463.
22. Changaris DG, Porter JL, Miller JJ, Levy RS. Des-Leu angiotensin I: biosynthesis and drinking response. Regul Pept 1988; 20: 273-280.
23. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843.
24. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
25. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captoprilinsensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-33243.
26. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991; 18: 763-773.
27. Snyder RA, Wintroub BU. Inhibition of angiotensinconverting enzyme by des-Leu10-angiotensin I: a potential mechanism of endogenous angiotensin-converting enzyme regulation. Biochim Biophys Acta 1986; 871: 1-5.
28. Snyder RA, Watt KW, Wintroub BU. A human platelet angiotensin I-processing system. Identification of components and inhibition of angiotensin-converting enzyme by product. J Biol Chem 1985; 260: 7857-7860.
29. Jackman HL, Massad MG, Sekosan M, et al. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension 2002; 39: 976-981.
30. Sadowski J, Badzynska B. Intrarenal vasodilator systems: NO, prostaglandins and bradykinin. An integrative approach. J Physiol Pharmacol 2008; 59(Suppl 9): 105-119.
31. Drummer OH, Kourtis S, Johnson H. Formation of angiotensin II and other angiotensin peptides from des-leu 10-angiotensin I in rat lung and kidney. Biochem Pharmacol 1988; 37: 4327-4333.
32. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58: 1078-1084.
33. Wilcox CS, Welch WJ. Thromboxane mediation of the pressor response to infused angiotensin II. Am J Hypertens 1990; 3: 242-249.
34. Coleman JK, Lee JI, Miller JM, Nuttall AL. Changes in cochlear blood flow due to intra-arterial infusions of angiotensin II (3-8) (angiotensin IV) in guinea pigs. Hear Res 1998; 119: 61-68.
35. Matys T, Pawlak R, Kucharewicz I, Chabielska E, Buczko W. Hypotensive effect of angiotensin II after AT1-receptor blockade with losartan. J Physiol Pharmacol 2000; 51: 161-166.
36. Mogielnicki A, Kramkowski K, Pietrzak L, Buczko W. Nmethylnicotinamide inhibits arterial thrombosis in hypertensive rats. J Physiol Pharmacol 2007; 58: 515-527.
37. Bjornsson TD, Schneider DE, Berger HJ. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989; 250: 154-161.
38. He S, Antovic A, Blomback M. Asimple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103: 355-361.
39. Buczko W, Mogielnicki A, Kramkowski K, Chabielska E. Aspirin and the fibrinolytic response. Thromb Res 2003; 110: 331-334.
40. Pawlak R, Chabielska E, Golatowski J, Azzadin A, Buczko W. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Thromb Haemost 1998; 79: 1208-1212.
41. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 2005; 288: F1183-F1190.
42. Schumacher WA, Heran CL, Youssef S, Megill JR, Michel I, Durham SK. Comparison of a thromboxane receptor antagonist and aspirin in experimental arterial thrombosis. Haemostasis 1993; 23: 219-228.
43. Schumacher WA, Steinbacher TE, Megill JR, Durham SK. A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin. J Pharmacol Toxicol Methods 1996; 35: 3-10.
44. Kawasaki T, Sato K, Suzuki K, et al. Enhancement of tissuetype plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis. Thromb Haemost 1998; 79: 663-667.
45. Guarini S. Ahighly reproducible model of arterial thrombosis in rats. J Pharmacol Toxicol Methods 1996; 35: 101-105.
46. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19(Suppl H): H11-H17.
47. Poplawski A. The effect o angiotensin II on the platelet aggregation induced by adenosine diphosphate, epinephrine and thrombin. Experientia 1970; 26: 86.
48. Swartz SL, Moore TJ. Effect of angiotensin II on collageninduced platelet activation in normotensive subjects. Thromb Haemost 1990; 63: 87-90.
49. Touyz RM, Schiffrin EL. Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension. Hypertension 1993; 22: 853-862.
50. Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens 2000; 14: 581-585.
51. Szczepanska-Sadowska E. Role of neuropeptides in central control of cardiovascular responses to stress. J Physiol Pharmacol 2008; 59(Suppl 8): 61-89.
52. Olszanecki R, Madej J, Suski M, Gebska A, Bujak-Gizycka B, Korbut R. Angiotensin metabolism in rat stomach wall: prevalence of angiotensin-(1-7) formation. J Physiol Pharmacol 2009; 60: 191-196.
53. Olszanecki R, Bujak-Gizycka B, Madej J, et al. Kaempferol, but not resveratrol inhibits angiotensin converting enzyme. J Physiol Pharmacol 2008; 59: 387-392.
54. Ardaillou R. Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens 1997; 6: 28-34.